Kanuma

Sebelipase Alfa, the active ingredient in Kanuma, is an enzyme replacement therapy presented as a solution for injection for intravenous use. It treats lysosomal acid lipase deficiency, including Wolman disease and cholesteryl ester storage disease, by restoring the missing enzyme activity in affected patients.

GNH USA supplies Kanuma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and research institutions worldwide. The company ensures quality assurance, cold‑chain logistics and regulatory compliance for each shipment.

Kanuma is used to treat lysosomal acid lipase deficiency and related disorders.

- Lysosomal acid lipase deficiency (LAL‑D): restores deficient enzyme activity, reducing lipid accumulation in organs. - Wolman disease: provides enzyme replacement that improves survival and organ function in infants with the severe form. - Cholesteryl ester storage disease: helps normalize lipid metabolism and liver function in patients with the milder phenotype.

Kanuma may be associated with a range of adverse reactions observed during clinical use.

Common Side Effects: - Infusion‑related reactions (e.g., flushing, chills) - Fever - Nausea - Headache

Serious or Rare Side Effects: - Anaphylaxis or severe hypersensitivity - Significant elevation of hepatic transaminases - Thrombocytopenia or bleeding disorders

When prescribing Kanuma, clinicians should observe several safety considerations.

- Monitor liver function tests: baseline and periodic assessments are recommended. - Assess for hypersensitivity: discontinue if severe allergic reactions occur. - Evaluate cardiac status: patients with pre‑existing heart disease should be observed during infusion. - Use with caution in infants and young children: dose adjustments may be required. - Adjust for severe renal impairment only under specialist guidance. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Kanuma can interact with other medicines; awareness of major and moderate interactions helps manage risk.

Major Interactions (Avoid): - Live vaccines: concurrent administration may reduce vaccine efficacy or increase adverse events. - Other enzyme replacement therapies: combined use may increase risk of immune reactions.

Moderate Interactions (Monitor Closely): - Anticoagulants (e.g., warfarin): monitor coagulation parameters as infusion may affect bleeding risk. - Immunosuppressants (e.g., tacrolimus): observe for enhanced immunosuppression. - CYP450 substrates: although not a primary pathway, monitor for unexpected changes in drug levels.